Our Approach
Botulinum neurotoxins have been shown to improve symptoms in depressed patients. Object Pharma is developing a unique botulinum neurotoxin, different than currently marketed products, for treatment of depression and other mental health disorders.
The problem:
Depression is among the most common mental disorders and is a leading cause of disability, affecting over 280 million people worldwide. Current treatments are inadequate. “…Up to 50% of individuals with major depressive disorder (MDD) do not recover after two antidepressant medication trials…”
Depression is on the rise, fueling a growing mental health crisis that requires urgent attention and better resources for prevention. Object Pharma is addressing the challenge with innovative solutions for mental health care.
Current Antidepressants
Nearly 40% of patients do not receive adequate
relief with oral medications
Most patients require at least 2 treatment medications,
which take 4-6 months to evaluate
Frequent “drug cycling”: no gold standard exists for
everyone (i.e.- trial and error)
Common Issues:
- SSRI/SNRI: feeling numb, weight gain, nausea,
loss of sexual function - TCA AE’s: Urinary retention
$327B
Estimated US economic costs due to major depressive disorder
65%
of treated patients require better, more-effective alternatives
Physicians are desperate for effective treatment innovations.
The solution – OP01:
OP01 is a unique botulinum neurotoxin that belongs to the same class of molecule as onabotulinumtoxinA. Object Pharma is developing OP01 exclusively for the treatment of mental health disorders.
Our first indication is major depressive disorder.
- OP01 can be used with current antidepressants
- OP01 is clinically unique and can deliver an effective solution to the global mental health epidemic
Expected Benefits – OP01:
- The BoNT class has demonstrated evidence of efficacy and safety in clinical trials of MDD
- No drug/drug interactions
- No ”wash out” period required before administering OP01
- An adjunctive treatment which may work synergistically (or) reduce patients’ need for existing antidepressants
- Can address current issues with MDD therapy in children and the elderly